TIDM0Y71

RNS Number : 2690L

Malin Corporation PLC

11 January 2021

Malin Corporation plc

Immunocore announces completion of $75 million Series C Financing

Dublin-Ireland, 11 January 2021 : Malin Corporation plc. (Euronext Growth Dublin:MLC) (Malin), a company investing in highly innovative life sciences companies, reports that Immunocore Limited (Immunocore), a Malin investee company, has today announced the completion of a $75 million Series C private financing round. Led by an existing investor in Immunocore, the Series C financing included support from existing investors and funds and accounts managed by BlackRock.

The proceeds will enable Immunocore to further expand and accelerate its growing clinical stage pipeline of ImmTAX(TM) molecules, including its lead programme, tebentafusp (IMCgp100). Malin did not participate in the financing round and the completion of the round had a marginal dilutive impact on Malin's ownership interest which remains at 7% of the issued share capital of Immunocore.

Immunocore also announced that it has closed a $100 million senior secured loan facility with Oxford Finance LLC and intends to use the loan proceeds for general corporate purposes and to have available as needed to fund a potential commercial launch of tebentafusp.

Today's announcements come after Immunocore announced in November 2020 that tebentafusp had demonstrated superior overall survival compared to investigator's choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma, a rare and aggressive form of melanoma which affects the eye. If approved, Immunocore believes tebentafusp would be the first new therapy for the treatment of metastatic uveal melanoma in 40 years.

Immunocore is a late-stage biotechnology company developing a novel class of TCR bispecific immunotherapies called ImmTAX designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Immunocore has five clinical stage programmes in oncology and infectious diseases, advanced pre-clinical programmes in autoimmune diseases and multiple earlier pre-clinical programmes.

A copy of Immunocore's press release is available on the company's website .

ENDS

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com

For further information please contact:

Malin

Jessica Bergin, Investor Relations & External Reporting

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

Davy Corporate Finance (Euronext Growth Adviser & Joint Broker)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

Liberum (Joint Broker)

Bidhi Bhoma / Euan Brown

Tel: +44 (0) 20 3100 2000

Powerscourt (Irish Media enquiries)

Eavan Gannon

Tel: +353 87 236 5973

malin@powerscourt-group.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFFLFFFFLEBBZ

(END) Dow Jones Newswires

January 11, 2021 07:05 ET (12:05 GMT)

Malin (LSE:0Y71)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Malin Charts.
Malin (LSE:0Y71)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Malin Charts.